Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC — MP-LALC  

Non Small Cell Lung Cancer Patients Clinical Trial

Official title: A Randomized Phase II Study of Pembrolizumab (MK-3475) as Maintainance Therapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer Treated With Definitive Chemo-radiotherapy

Status Not yet recruiting

Clinical Trial Summary

Maintainance therapy in patients with unresectable stage III, NSCLC Stage IIIA-B, unresectable, NSCLC, treated with definitive Chemo-Radiotherapy

Clinical Trial Description

This is an Italian multi-center randomized phase II trial (randomization 2:1) of intravenous (IV) MK-3475 (Pembrolizumab) versus observation as a maintenance therapy after chemo-radiotherapy (either concomitant or sequential, regardless of the type of chemotherapy used) in unresectable stage IIIA-IIIB non small cell lung cancer (NSCLC) patients. ;

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non Small Cell Lung Cancer Patients

• NCT number: NCT03379441
• Study type: Interventional
• Source: University of Turin, Italy
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: January 1, 2018
• Completion date: January 1, 2023